[go: up one dir, main page]

MX2008010187A - Tratamiento de distrofia muscular de duchenne. - Google Patents

Tratamiento de distrofia muscular de duchenne.

Info

Publication number
MX2008010187A
MX2008010187A MX2008010187A MX2008010187A MX2008010187A MX 2008010187 A MX2008010187 A MX 2008010187A MX 2008010187 A MX2008010187 A MX 2008010187A MX 2008010187 A MX2008010187 A MX 2008010187A MX 2008010187 A MX2008010187 A MX 2008010187A
Authority
MX
Mexico
Prior art keywords
optionally substituted
aryl
represent
different
same
Prior art date
Application number
MX2008010187A
Other languages
English (en)
Inventor
Graham Michael Wynne
Richard Storer
Stephen Paul Wren
Peter David Johnson
Damien Price
Olivier De Moor
Gary Nugent
Andrew Mulvaney
Richard Joseph Pye
Colin Richard Dorgan
Original Assignee
Summit Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0602768A external-priority patent/GB0602768D0/en
Priority claimed from GB0614690A external-priority patent/GB0614690D0/en
Priority claimed from GB0619281A external-priority patent/GB0619281D0/en
Priority claimed from GB0623983A external-priority patent/GB0623983D0/en
Application filed by Summit Corp Plc filed Critical Summit Corp Plc
Publication of MX2008010187A publication Critical patent/MX2008010187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

Se describen compuestos de fórmula (1): A1, A2, A3 y A4, los cuales pueden ser iguales o diferentes, representan N ó CR1 X es un grupo divalente seleccionado de O, S(O)n, C=W, NR4, NC(=O)R5 y CR6R7, W es O, S, NR20, Y es N ó CR6, uno de los radicales R4, R5, R6, R8, R9 y NR20 representa -L-R3, en el cual L es un enlace sencillo o un grupo ligador, además, R1, R3-R9, que pueden ser iguales o diferentes, independientemente representan hidrógeno o un sustituyente, y R20 representa hidrógeno, hidroxilo, alquilo opcionalmente sustituido por arilo, alcoxi opcionalmente sustituido por arilo, arilo, CN, alcoxi opcionalmente sustituido, ariloxi opcionalmente sustituido, alcanoilo opcionalmente sustituido, aroilo opcionalmente sustituido, NO2, NR30R31, en los cuales R30 y R31, los cuales pueden ser iguales o diferentes, representan hidrógeno, alquilo opcionalmente sustituido ó arilo opcionalmente sustituido; además, uno de R30 y R31 puede representar alcanoilo opcionalmente sustituido ó aroilo opcionalmente sustituido, n representa un entero de 0 a 2, además, cuando un par adyacente de A1-A4 cada uno representa CR1, entonces los átomos de carbono contiguos, junto con sus sustituyentes, pueden formar un anillo B, cuando X es CR6R7, R6 y R7, junto con el átomo de carbono al que están unidos, pueden formar un anillo C, o una sal aceptada para uso farmacéutico de éstos, en la fabricación de un medicamento para el tratamiento terapéutico y/o profiláctico de distrofia muscular de Duchenne, distrofia muscular de Becker ó caquexia.
MX2008010187A 2006-02-10 2007-02-09 Tratamiento de distrofia muscular de duchenne. MX2008010187A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0602768A GB0602768D0 (en) 2006-02-10 2006-02-10 Treatment of muscular dystrophy
GB0614690A GB0614690D0 (en) 2006-07-24 2006-07-24 Method of treatment of duchenne muscular dystrophy
GB0619281A GB0619281D0 (en) 2006-09-29 2006-09-29 Treatment of duchenne muscular dystrophy
GB0623983A GB0623983D0 (en) 2006-11-30 2006-11-30 Treatment of duchenne muscular dystrophy
PCT/GB2007/050055 WO2007091106A2 (en) 2006-02-10 2007-02-09 Treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2008010187A true MX2008010187A (es) 2008-10-31

Family

ID=38229987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010187A MX2008010187A (es) 2006-02-10 2007-02-09 Tratamiento de distrofia muscular de duchenne.

Country Status (17)

Country Link
US (2) US8518980B2 (es)
EP (1) EP1986633B1 (es)
JP (1) JP5376956B2 (es)
KR (2) KR101472248B1 (es)
AU (1) AU2007213451B2 (es)
BR (1) BRPI0707719A2 (es)
CA (1) CA2641880C (es)
CY (1) CY1115657T1 (es)
DK (1) DK1986633T3 (es)
ES (1) ES2522290T3 (es)
IL (2) IL193315A (es)
MX (1) MX2008010187A (es)
NZ (1) NZ570625A (es)
PL (1) PL1986633T3 (es)
PT (1) PT1986633E (es)
SI (1) SI1986633T1 (es)
WO (1) WO2007091106A2 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101472248B1 (ko) 2006-02-10 2014-12-16 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
SG173312A1 (en) * 2006-06-23 2011-08-29 Abbott Lab Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
RS55735B1 (sr) 2007-08-03 2017-07-31 Summit (Oxford) Ltd Kombinacije lekova za lečenje dišenove mišićne distrofije
GB0715938D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
WO2009080788A2 (en) * 2007-12-21 2009-07-02 Universite Catholique De Louvain Antibacterial agents
US20130023498A1 (en) * 2008-02-20 2013-01-24 The Wistar Institute and North Carolina State University MicroRNA Modulators and Method for Identifying and Using the Same
KR101578342B1 (ko) * 2008-03-31 2015-12-16 가부시키가이샤 시세이도 주름을 방지 또는 개선하기 위한 경구, 주사, 피부 외용제 및 미용 방법
JP5369854B2 (ja) * 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
US20110065728A1 (en) * 2008-05-14 2011-03-17 Otsuka Pharmaceutical Factory, Inc. Lipoprotein lipase-activating compositions comprising benzene derivatives
WO2009155017A2 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted azabenzoxazoles
GB0815369D0 (en) * 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2737694C (en) 2008-09-26 2013-07-02 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2352374B1 (en) 2008-10-29 2014-09-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
WO2010108187A2 (en) * 2009-03-20 2010-09-23 Brandeis University Compounds and methods for treating mammalian gastrointestinal microbial infections
GB0905664D0 (en) * 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
GB0905667D0 (en) * 2009-04-02 2009-05-20 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
CA2771026A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
JP5540640B2 (ja) 2009-10-07 2014-07-02 住友化学株式会社 複素環化合物及びその有害節足動物防除用途
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
CN103037694B (zh) 2010-06-23 2014-08-13 住友化学株式会社 防治有害节肢动物的组合物和杂环化合物
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
CN104334196B (zh) * 2012-02-16 2018-04-10 Atyr 医药公司 用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
CN104245694B (zh) 2012-03-06 2017-11-03 特殊化合物服务有限公司 具有治疗活性的氨基亚甲基吡唑啉酮
EP2636673A1 (en) * 2012-03-06 2013-09-11 Compound Handling B.V. Aminomethylene pyrazolones with therapeutic activity
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
MX2015004500A (es) 2012-10-17 2015-07-06 Hoffmann La Roche Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp).
ITMI20122065A1 (it) * 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
EP2948438A4 (en) * 2013-01-23 2016-10-05 Univ Chicago METHOD AND COMPOSITIONS FOR INHIBITING THE HUMAN COPPER TRAFFICKING PROTEIN ATOX1 AND CCS
JP6397479B2 (ja) 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
RU2681537C2 (ru) * 2014-04-14 2019-03-07 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia
WO2016021706A1 (ja) * 2014-08-08 2016-02-11 カズマパートナーズ株式会社 縮合複素環化合物
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
KR101995655B1 (ko) * 2015-03-31 2019-07-02 세이카 가부시키가이샤 방향족 디아민 및 그 중간체, 및 이들의 제조방법
JP6603035B2 (ja) * 2015-03-31 2019-11-06 セイカ株式会社 アミノ基及び／又はニトロ基を有するベンゾオキサゾール−２−イル−ジフェニルエーテル及びその誘導体、並びにこれらの製造方法
JP6603043B2 (ja) * 2015-05-26 2019-11-06 セイカ株式会社 芳香族ジアミン及びその中間体、並びにこれらの製造方法
AU2016284942B2 (en) 2015-06-22 2020-08-20 Actelion Pharmaceuticals Ltd NADPH oxidase 4 inhibitors
US20180296532A1 (en) * 2015-09-18 2018-10-18 The Scripps Research Institute RNA-Focused Small Molecules for Inhibiting RNA Toxicity in Myotonic Dystrophy
KR20190026647A (ko) 2016-03-30 2019-03-13 서밋 (옥스포드) 리미티드 뒤쉔 근육 영양장애의 치료용 조성물
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
US12473266B2 (en) 2018-10-10 2025-11-18 Albert Einstein College Of Medicine Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
KR102132459B1 (ko) 2019-10-02 2020-07-09 손영재 알루미늄 커튼월 구조
WO2022123314A1 (en) * 2020-12-11 2022-06-16 Tmem16A Limited Benzimidazole derivatives for treating respiratory disease
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
CN114057662A (zh) * 2021-12-10 2022-02-18 湖南第一师范学院 一种Tafamidis的合成方法
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025057074A1 (en) 2023-09-13 2025-03-20 Suven Life Sciences Limited N-aryl benzamide derivatives as p2x7 receptor antagonists
CN117964572A (zh) * 2024-03-01 2024-05-03 浙江鼎龙科技股份有限公司 2-(2-羟基-4-氨基苯基)-5-氨基苯并噁唑的制备方法
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628696A (es) * 1962-02-21
CH561242A5 (es) 1971-08-10 1975-04-30 Ciba Geigy Ag
US3993659A (en) 1971-08-10 1976-11-23 Ciba-Geigy Corporation Bis-benzoxazolyl-naphthalenes as optical brighteners
GB1488003A (en) * 1973-10-23 1977-10-05 Lilly Industries Ltd 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals
CH617809GA3 (es) 1975-10-10 1980-06-30
DE2619547A1 (de) * 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4110246A (en) 1976-05-13 1978-08-29 Hoechst Aktiengesellschaft Mixture of benzoxazole derivatives
DE3027479A1 (de) 1980-07-19 1982-03-04 Hoechst Ag, 6000 Frankfurt Mischungen von optischen aufhellern und deren verwendung
JPS615071A (ja) 1984-06-15 1986-01-10 Fuji Photo Film Co Ltd ベンゾオキサゾ−ル誘導体
DE3617451A1 (de) 1986-05-23 1987-11-26 Hoechst Ag Sulfonat- oder sulfonamidgruppen-haltige bis-benzoxazolylnaphthaline, verfahren zu deren herstellung und deren verwendung
JP2615805B2 (ja) 1988-04-15 1997-06-04 ミノルタ株式会社 感光体
DE3819051A1 (de) 1988-06-04 1989-12-07 Agfa Gevaert Ag Farbfotografisches aufzeichnungsmaterial
JPH0369292A (ja) 1989-08-08 1991-03-25 Sharp Corp スロー再生における縦揺れ補正装置
ES2092080T3 (es) 1991-08-08 1996-11-16 Ciba Geigy Ag Colorantes, procedimiento para su obtencion y su utilizacion.
ES2157268T5 (es) 1994-02-24 2004-12-01 SYMRISE GMBH & CO KG Preparados cosmeticos y dermatologicos que contienen acidos fenilen-1,4-bisbencimidazolsulfonicos.
US6004719A (en) 1994-04-25 1999-12-21 Polaroid Corporation Imaging medium and process for producing an image
EP0767809B1 (en) 1994-06-30 2004-01-21 Minnesota Mining And Manufacturing Company Cure-indicating molding and coating composition
AU690302B2 (en) 1994-06-30 1998-04-23 Dade Behring Inc. Bioactive porous partition members
JPH0815917A (ja) 1994-07-01 1996-01-19 Mitsubishi Chem Corp 静電荷像現像用帯電制御剤
JPH08175992A (ja) 1994-12-21 1996-07-09 Sagami Chem Res Center 神経成長因子産生促進剤および縮環型オキサゾール化合物
JP3216458B2 (ja) * 1994-12-28 2001-10-09 富士レビオ株式会社 アミド誘導体
US5567843A (en) 1995-03-20 1996-10-22 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid)azoles and 2-aminoaryl aminobenz(ox, thi, imid)azoles
US6222044B1 (en) 1995-03-20 2001-04-24 The Dow Chemical Company Process for making 2-aryl benz (ox, thi, imid) azoles and 2-aminoaryl aminobenz (ox, thi, imid) azoles
US5977101A (en) 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
JP3069292B2 (ja) 1996-06-13 2000-07-24 株式会社分子バイオホトニクス研究所 カテコール化合物及びバニリル化合物の蛍光検出用固相化試薬および検出方法
US5645948A (en) 1996-08-20 1997-07-08 Eastman Kodak Company Blue organic electroluminescent devices
US6110638A (en) 1996-11-27 2000-08-29 Polaroid Corporation Process and composition for generation of acid
US5914213A (en) 1996-11-27 1999-06-22 Polaroid Corporation Process and composition for generation of acid
FR2757389B1 (fr) 1996-12-24 1999-02-05 Oreal Composition cosmetique filtrante
US6177572B1 (en) 1997-08-20 2001-01-23 Sepracor, Inc. Solid and liquid-phase synthesis of benzoxazoles and benzothiazoles and their use
WO1999016761A1 (fr) * 1997-09-30 1999-04-08 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes
JPH11171881A (ja) 1997-09-30 1999-06-29 Mitsubishi Chemical Corp 含酸素複素環誘導体
US6312822B1 (en) 1998-05-28 2001-11-06 Eastman Chem Co Dispersion aids for optical brighteners in polyolefins
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6436558B1 (en) 1998-08-07 2002-08-20 Fuji Photo Film Co., Ltd. Organic electroluminescence element
SE9804465D0 (sv) 1998-12-22 1998-12-22 Amersham Pharm Biotech Ab A method for the removal/purification of serum albumins and means for use in the method
FR2789581B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de benzotriazole, un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
FR2789582B1 (fr) 1999-02-12 2001-05-04 Oreal Compositions photoprotectrices contenant un derive de bis-resorcinyl triazine et un compose a groupements benzoazolyle ou benzodiazolyle
JP2002544132A (ja) 1999-05-07 2002-12-24 ビーエーエスエフ アクチェンゲゼルシャフト 除草剤としての４−（３’，４’−ヘテロシクリルベンゾイル）ピラゾール
AU4755600A (en) 1999-05-07 2000-11-21 Basf Aktiengesellschaft Benzohetero cyclylcyclo hexenones and their use as herbicides
FR2794645B1 (fr) 1999-06-08 2001-08-10 Oreal Compositions photoprotectrices contenant un compose hydrocarbone bis-hydroxyphenylbenzotriazole et un compose a groupements benzoazolyle ou benzodiazolyle
JP2001039034A (ja) 1999-08-03 2001-02-13 Mitsui Chemicals Inc 光記録媒体
GB2353038A (en) 1999-08-12 2001-02-14 Eastman Chem Co Polyolefin composition comprising non-migrating optical brightener
ATE289291T1 (de) * 1999-09-24 2005-03-15 Ono Pharmaceutical Co Hydroxamsäurederivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven wirkstoff enthalten
US6565987B2 (en) 1999-11-12 2003-05-20 Eastman Chemical Company Non-exuding optically brightened polyolefin blends
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
JP2001261664A (ja) 2000-03-15 2001-09-26 Konica Corp ハロゲン化銀写真感光材料、画像形成方法並びに化合物及びその合成方法
US7361678B2 (en) 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
PT1334091E (pt) 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
US6716413B1 (en) 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
WO2002044189A1 (fr) 2000-11-30 2002-06-06 Canon Kabushiki Kaisha Element luminescent et afficheur
FR2818142B1 (fr) 2000-12-18 2003-12-26 Oreal Compositions antisolaires a base d'un base melange synergetique de filtres et utilisations
JP2003005356A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20050261298A1 (en) 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
JP4294917B2 (ja) 2002-07-02 2009-07-15 三井化学株式会社 光記録媒体およびオキサゾール化合物
EP1547996A4 (en) 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004069394A2 (en) 2003-02-03 2004-08-19 The Trustees Of Columbia University In The City Of New York Synthetic method for direct arylation of heterocyclic arenes
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
JP2007516227A (ja) 2003-05-16 2007-06-21 アンビット バイオサイエンシス コーポレーション ピロール化合物およびその使用
EP1635823A1 (en) 2003-05-20 2006-03-22 TransTech Pharma Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
US7527916B2 (en) 2003-09-22 2009-05-05 Agfa Graphics, N.V. Photopolymerizable composition
US7097888B2 (en) 2003-12-15 2006-08-29 Eastman Kodak Company Aligned liquid crystal layer containing azolium salts and process for increasing the tilt
US7592373B2 (en) * 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
CA2555313A1 (en) 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1776086A2 (en) 2004-08-09 2007-04-25 Ciba Specialty Chemicals Holding Inc. Use of fluorescent whitening agents as antimicrobials
CN101006159B (zh) 2004-08-19 2011-11-09 Lg化学株式会社 包括缓冲层的有机发光器件及其制备方法
WO2006044456A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
BRPI0406040B1 (pt) 2004-10-21 2018-09-11 Universidade Federal Do Rio De Janeiro - Ufrj compostos capazes de absorver radiação ultravioleta, composições contendo os mesmos e processos para sua preparação
WO2006051410A1 (en) * 2004-11-15 2006-05-18 Pfizer Inc. Azabenzoxazoles for the treatment of cns disorders
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CA2599989A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
FR2889700B1 (fr) 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
JP2007086165A (ja) 2005-09-20 2007-04-05 Fujifilm Corp 感光性組成物、これを用いた平版印刷版原版及び画像記録方法
KR100890862B1 (ko) 2005-11-07 2009-03-27 주식회사 엘지화학 유기 발광 소자 및 이의 제조 방법
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
ES2455166T3 (es) 2005-12-02 2014-04-14 Sachem, Inc. Procedimiento de cromatografía de desplazamiento de intercambio aniónico
KR101213485B1 (ko) 2006-01-27 2012-12-18 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101213486B1 (ko) 2006-02-02 2012-12-20 삼성디스플레이 주식회사 유기 금속 착물 및 이를 이용한 유기 전계 발광 소자
KR101472248B1 (ko) 2006-02-10 2014-12-16 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
WO2007096362A1 (en) 2006-02-21 2007-08-30 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
JP4649645B2 (ja) 2006-03-10 2011-03-16 独立行政法人科学技術振興機構 光学活性アルコール化合物の製法
KR101325062B1 (ko) 2006-05-19 2013-11-05 삼성디스플레이 주식회사 발광 이종 핵 구리-이리듐 착체 및 이를 이용한 유기 전계발광 소자
AU2007257959A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy

Also Published As

Publication number Publication date
CY1115657T1 (el) 2017-01-25
AU2007213451B2 (en) 2013-02-07
CA2641880C (en) 2014-09-09
ES2522290T3 (es) 2014-11-14
IL193315A (en) 2016-02-29
JP2009526034A (ja) 2009-07-16
EP1986633A2 (en) 2008-11-05
BRPI0707719A2 (pt) 2011-05-10
WO2007091106A2 (en) 2007-08-16
SI1986633T1 (sl) 2015-03-31
DK1986633T3 (da) 2014-11-03
KR101426093B1 (ko) 2014-08-01
KR20090010025A (ko) 2009-01-28
US20090075938A1 (en) 2009-03-19
HK1125577A1 (en) 2009-08-14
IL228598A0 (en) 2013-12-31
KR20130129476A (ko) 2013-11-28
KR101472248B1 (ko) 2014-12-16
US8518980B2 (en) 2013-08-27
IL193315A0 (en) 2009-09-22
JP5376956B2 (ja) 2013-12-25
PL1986633T3 (pl) 2015-01-30
PT1986633E (pt) 2014-11-05
EP1986633B1 (en) 2014-07-30
CA2641880A1 (en) 2007-08-16
WO2007091106A3 (en) 2008-03-06
NZ570625A (en) 2011-10-28
US20140018320A1 (en) 2014-01-16
AU2007213451A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
MX2008010187A (es) Tratamiento de distrofia muscular de duchenne.
US6271254B1 (en) Pharmaceutical compositions containing R-α-lipoic acid or S-α-lipoic acid as active ingredient
MX2025000642A (es) Compuestos macrociclicos para el tratamiento de cancer
AU2012249646B2 (en) Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
JP2008526999A5 (es)
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
BRPI0413876A (pt) tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
GB0612423D0 (en) Therapeutic agents
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
PH12020550065A1 (en) Hepatitis b antiviral agents
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
JP2009526034A5 (es)
MX2010007375A (es) Nuevos derivados de lupano.
MX2010007374A (es) Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos.
MX2013000474A (es) Derivados de arilamida novedosos que tienen propiedades antiandrogenicas.
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
MX2021003253A (es) Heterociclos funcionalizados como agentes antivirales.
CA2617817A1 (en) Thiazole derivatives for treating or preventing sleep disorders
WO2021055425A3 (en) Functionalized heterocycles as antiviral agents

Legal Events

Date Code Title Description
FG Grant or registration